Gene Editing is the ability to make highly specific changes in the DNA sequence of a living organism, essentially customizing its genetic makeup. It demonstrates great potential in gene research, gene therapy and genetic improvement. The Gene Editing concept includes major US-listed companies whose businesses are involved in gene editing.
- 1312.177
- +5.418+0.41%
EDIT, CLNE and NIU Are Among After Hour Movers
Bluebird Bio Faces Nasdaq Compliance Challenge and Delays
Bluebird Bio Receives Non-compliance Notice From Nasdaq
$100B Vertex Pharma Working To Recreate $10B Cystic Fibrosis Success - This Time Focused On Pain Management Drugs
Vertex Pharmaceuticals Inc's (NASDAQ:VRTX) blockbuster drug Trikafta for cystic fibrosis (CF) has shown remarkable efficacy, potentially extending the lives of some patients by up to 45 years. Despite
HC Wainwright & Co. Reiterates Buy on Apellis Pharmaceuticals, Maintains $92 Price Target
HC Wainwright & Co. analyst Douglas Tsao reiterates Apellis Pharmaceuticals with a Buy and maintains $92 price target.
Vertex Announces European Commission Approval For Kalydeco To Treat Infants With Cystic Fibrosis Ages 1 Month And Older
Vertex Announces European Commission Approval For Kalydeco To Treat Infants With Cystic Fibrosis Ages 1 Month And Older
Buy Rating Affirmed for Apellis Pharmaceuticals Amid Positive Outlook and Growth Potential
Apellis Pharmaceuticals Says EMA Moves Pegcetacoplan Application to Last Phase of Initial Assessment
Apellis Pharmaceuticals (APLS) said Friday that the review of the marketing authorization application for pegcetacoplan has been reset to day 180, the last phase of the initial assessment by the Europ
The Zacks Analyst Blog Highlights Biogen, Bristol Myers Squibb, Incyte and Vertex Pharmaceuticals
Declining Stock and Solid Fundamentals: Is The Market Wrong About Agilent Technologies, Inc. (NYSE:A)?
Apellis Pharmaceuticals Shares Are Trading Higher After the European Medicines Agency Resets Pegcetacoplan Review for Geographic Atrophy to Day 180 of Initial Assessment.
Apellis Pharmaceuticals Shares Are Trading Higher After the European Medicines Agency Resets Pegcetacoplan Review for Geographic Atrophy to Day 180 of Initial Assessment.
European Medicines Agency Has Reset The Review Of Apellis Pharmaceuticals' Intravitreal Pegcetacoplan For Geographic Atrophy To The Last Phase Of The Initial Assessment (Day 180). Apellis Anticipates An Opinion From CHMP No Later Than July 2024
European Medicines Agency Has Reset The Review Of Apellis Pharmaceuticals' Intravitreal Pegcetacoplan For Geographic Atrophy To The Last Phase Of The Initial Assessment (Day 180). Apellis Anticipates
Institutional Owners May Consider Drastic Measures as Intellia Therapeutics, Inc.'s (NASDAQ:NTLA) Recent US$125m Drop Adds to Long-term Losses
Key Insights Significantly high institutional ownership implies Intellia Therapeutics' stock price is sensitive to their trading actions The top 11 shareholders own 50% of the company Recent sale
Analysts Have Conflicting Sentiments on These Healthcare Companies: Apellis Pharmaceuticals (APLS), Quest Diagnostics (DGX) and Healthcare Services (HCSG)
Impact of Izervay's Growth on Apellis Pharmaceuticals: Maintaining a Hold Rating Amidst Rising Competition
Apellis Announces Pegcetacoplan MAA Review Has Been Reset to Day 180 of Initial Assessment by European Medicines Agency (EMA)
Decision by EMA follows recent judgment by the Court of Justice of the European Union regarding the organization of EMA's expert groupsApellis anticipates a CHMP opinion no later than July 2024WALTHAM
(VRTX) - Analyzing Vertex Pharmaceuticals's Short Interest
Vertex Pharmaceuticals's (NYSE:VRTX) short percent of float has fallen 3.75% since its last report. The company recently reported that it has 3.98 million shares sold short, which is 1.54% of all regu
9 Stocks That Thrive When Interest Rates Are Higher
Though economic stress could be on the way, a few groups of stocks can benefit.
Apellis Pharmaceuticals Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/25/2024 76.79% Needham → $85 Reiterates Buy → Buy 04/17/2024 18.55% Wedbush $67 → $57 Maintains Neutral
Maintaining Market Dominance: Strong Buy Rating on Apellis Pharmaceuticals With a Target Price of $85